Who is sponsoring NCT00534638?

NCT00534638 is sponsored by GlaxoSmithKline.

What condition does NCT00534638 study?

NCT00534638 studies Infections, Papillomavirus.

What drugs are being tested in NCT00534638?

Interventions: Cervarix, Engerix-B.

What is the status of NCT00534638?

NCT00534638 is currently COMPLETED.

Last reviewed 2019-11-15 · How we verify

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

NCT00534638 PHASE4 COMPLETED Results posted

Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE4
Status	COMPLETED
Enrolment	34412
Start date	Thu Oct 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Infections, Papillomavirus

Interventions

Cervarix
Engerix-B

Countries

Finland